Company intelligence / Profile preview

Oncentric

San Francisco, California, United Statesconcentricusa.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Concentric Analgesics is developing novel non-opioid therapeutics targeting the TRPV1 receptor to manage acute and chronic pain. Their approach aims to provide extended relief at the source of pain with limited systemic exposure and reduced opioid consumption. The lead candidates are designed as single-injection treatments that offer durable relief without numbness or muscle weakness. No detailed clinical results are publicly available as of now.

Therapeutic areas: Neurology
Modalities: Small moleculesProdrugs
Industry: Biotech

Beyond the preview

Go deeper on Oncentric.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncentric.

Explore the full profile